FDA announced that it has achieved its first-year goals in implementing its roadmap to reduce animal testing in preclinical studies.
The Centers for Medicare and Medicaid Services and FDA announced a new coverage pathway—called the Regulatory Alignment for Predictable and Immediate Device, or RAPID pathway—designed to expedite access to certain FDA-designated Class II and Class III Breakthrough devices for people with Medicare.
